aap Implantate reported 3Q19 revenue of €2.8 million (USD $3.1 million), -0.1% vs. 3Q18.
- The company expects 2019 sales in the range of $12.4 (+1.7%) to $14.6 million (+20.1%)
- The decline in the U.S. was characterized as “temporary” due to the termination of a distributor sales relationship; since late September, weekly U.S. sales are growing at double the rate of the prior year
- Received approval for a human clinical study of their silver coating technology for implants and has started generating preclinical data for resorbable magnesium implant technology
- aap plans to launch the polyaxial LOCTEQ foot and calcaneus system in the U.S. in 2020
- ORTHOWORLD projects aap Implantate full year 2019 revenue of $12.9 million, +5.8% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19 | 3Q18 | $ Chg | % Chg | |
---|---|---|---|---|
Trauma | $3.1 | $3.1 | ($0.0) | (0.1%) |
9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
---|---|---|---|---|
Trauma | $9.8 | $9.3 | $0.5 | 5.6% |
Geographic Sales
3Q19 | 3Q18 | $ Chg | % Chg | |
---|---|---|---|---|
US | $0.5 | $0.5 | ($0.0) | (3.5%) |
Ex-US | $2.6 | $2.6 | $0.0 | 0.6% |
Total | $3.1 | $3.1 | ($0.0) | (0.1%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
aap Implantate reported 3Q19 revenue of €2.8 million (USD $3.1 million), -0.1% vs. 3Q18.
The company expects 2019 sales in the range of $12.4 (+1.7%) to $14.6 million (+20.1%)
The decline in the U.S. was characterized as “temporary” due to the termination of a distributor sales relationship; since late September, weekly U.S. sales...
aap Implantate reported 3Q19 revenue of €2.8 million (USD $3.1 million), -0.1% vs. 3Q18.
- The company expects 2019 sales in the range of $12.4 (+1.7%) to $14.6 million (+20.1%)
- The decline in the U.S. was characterized as “temporary” due to the termination of a distributor sales relationship; since late September, weekly U.S. sales are growing at double the rate of the prior year
- Received approval for a human clinical study of their silver coating technology for implants and has started generating preclinical data for resorbable magnesium implant technology
- aap plans to launch the polyaxial LOCTEQ foot and calcaneus system in the U.S. in 2020
- ORTHOWORLD projects aap Implantate full year 2019 revenue of $12.9 million, +5.8% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19 | 3Q18 | $ Chg | % Chg | |
---|---|---|---|---|
Trauma | $3.1 | $3.1 | ($0.0) | (0.1%) |
9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
---|---|---|---|---|
Trauma | $9.8 | $9.3 | $0.5 | 5.6% |
Geographic Sales
3Q19 | 3Q18 | $ Chg | % Chg | |
---|---|---|---|---|
US | $0.5 | $0.5 | ($0.0) | (3.5%) |
Ex-US | $2.6 | $2.6 | $0.0 | 0.6% |
Total | $3.1 | $3.1 | ($0.0) | (0.1%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.